[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Bagher-Ebadian H, Nagaraja TN, Paudyal R, Whitton P, Panda S, Fenstermacher JD, Ewing JR: MRI estimation of contrast agent concentration in tissue using a neural network approach. Magn Reson Med; 2007 Aug;58(2):290-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI estimation of contrast agent concentration in tissue using a neural network approach.
  • Using an MRI T(1) by multiple readout pulses (TOMROP) image set, an adaptive neural network (ANN) was trained to directly estimate the concentration of a contrast agent (CA), gadolinium-bovine serum albumin (Gd-BSA), in tissue.
  • In nine rats implanted with a 9L cerebral tumor, MRI acquisition of TOMROP inversion-recovery data was followed by quantitative autoradiography (QAR) using radioiodinated serum albumin (RISA).
  • [MeSH-major] Brain Neoplasms / diagnosis. Contrast Media / pharmacokinetics. Magnetic Resonance Imaging / methods. Neural Networks (Computer). Serum Albumin, Bovine / pharmacokinetics
  • [MeSH-minor] Animals. Area Under Curve. Disease Models, Animal. Image Processing, Computer-Assisted. Iodine Radioisotopes. ROC Curve. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17654573.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS23393; United States / NHLBI NIH HHS / HL / R01 HL70023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes; 0 / Serum Albumin, Bovine; 0 / gadolinium-bovine serum albumin complex
  •  go-up   go-down


2. Kurimoto M, Takaiwa A, Nagai S, Hayashi N, Endo S: Anomia for people's names after left anterior temporal lobe resection--case report. Neurol Med Chir (Tokyo); 2010 Jan;50(1):36-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old man was admitted to our hospital with an intrinsic brain tumor in the left anterior temporal lobe.
  • Preoperative sodium thiopental test demonstrated left hemispheric dominance.
  • Awake craniotomy was performed for dominant-hemispheric tumor resection using language mapping to identify the stimulation-induced positive language area.
  • This case report and other sporadic cases with this type of deficit reveal the left anterior temporal lobe is an important brain area for retrieving people's names.
  • [MeSH-major] Anomia / etiology. Brain Neoplasms / complications. Glioblastoma / complications. Neurosurgical Procedures / adverse effects. Postoperative Complications / etiology. Temporal Lobe / pathology
  • [MeSH-minor] Brain Mapping. Craniotomy. Disability Evaluation. Dominance, Cerebral / physiology. Drug Therapy. Fatal Outcome. Humans. Language. Language Tests. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neuropsychological Tests. Preoperative Care. Radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098023.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Zanetta F, Di Dio G, Savastio S, Saccagno A, Petri A, Bellone S, Maghnie M, Bona G: [Germinoma: a rare cerebral tumor causing central diabetes insipidus in childhood]. Minerva Pediatr; 2008 Feb;60(1):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Germinoma: a rare cerebral tumor causing central diabetes insipidus in childhood].
  • Germinoma represents 7.8% of cerebral tumors in pediatric age and 50-65% of germ cell cerebral tumors.
  • Clinical presentation depends on tumor localization.
  • Pineal lesions generally determine symptoms due to the compression of cerebral structures, causing Parinaud syndrome, while hypothalamic lesions are often characterized by diabetes insipidus, hypopituitarism and visual defects.
  • [MeSH-major] Diabetes Insipidus / diagnosis. Diabetes Insipidus / etiology. Germinoma / complications. Germinoma / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antidiuretic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Deamino Arginine Vasopressin / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Treatment Outcome


Advertisement
4. Collombet JM, Four E, Fauquette W, Burckhart MF, Masqueliez C, Bernabé D, Baubichon D, Lallement G: Soman poisoning induces delayed astrogliotic scar and angiogenesis in damaged mouse brain areas. Neurotoxicology; 2007 Jan;28(1):38-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliotic scar formation and angiogenesis are two biological events involved in the tissue reparative process generally occurring in the brain after mechanically induced injury, ischemia or cerebral tumor development.
  • For the first time, in this study, neo-vascularization and glial scar formation were investigated in the brain of soman-poisoned mice over a 3-month period after nerve agent exposure (1.2 LD50 of soman).
  • Reactive astroglial cells were located only in damaged cerebral regions where H&P-stained eosinophilic neurons were found.
  • [MeSH-minor] Animals. Cell Death / drug effects. Claudin-5. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry. Membrane Proteins / biosynthesis. Mice. Neuroglia / drug effects. Neuroglia / pathology. Neurons / pathology. Vascular Endothelial Growth Factor A / biosynthesis

  • Hazardous Substances Data Bank. SOMAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949671.001).
  • [ISSN] 0161-813X
  • [Journal-full-title] Neurotoxicology
  • [ISO-abbreviation] Neurotoxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Claudin-5; 0 / Cldn5 protein, mouse; 0 / Glial Fibrillary Acidic Protein; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; 96-64-0 / Soman
  •  go-up   go-down


5. Fuentes García MI, Mostaza Fernández JL, García López N, Olivares Fernández C, Palomo de los Reyes MJ: [Extragonadal germ cell tumor in HIV+ female]. An Med Interna; 2004 Aug;21(8):397-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extragonadal germ cell tumor in HIV+ female].
  • [Transliterated title] Tumor de células germinales extragonadal en mujer VIH+.
  • Although there is no evidence of relationship between this sort of tumor and HIV infection they can appear at the same time in a patient, because in both cases the maximum incidence occurs in patients in the same age group.
  • We present the case of a 27 years old woman, poly-drug user, with a recently diagnosis of HIV infection, who was admitted to clinic because of infection and shortage of breath, and develops during her hospitalization diarrhoea, generalized tonic-clonic seizure and left hemiparesis.
  • Complementary tests showed us diffuse interstitial pulmonary pattern, mediastinal mass with intrathoracic adenopathies, cerebral tumor and diffuse intestinal enlargement.
  • The breath infection got better with a wide-ranging antibiotic treatment, which included cotrimoxazol and levofloxacin, but the brain tumor didńt get better with the antitoxoplasma treatment.
  • The clinical presentation simulated in the beginning a disseminated lymphoma, in a HIV+ patient; nevertheless, after receiving the result of the biopsy of a supraclavicular adenopathy and a b-HCG, an extragodanal germ cell tumor was diagnosed.
  • [MeSH-major] Germinoma / complications. HIV Infections / complications. HIV-1. Mediastinal Neoplasms / complications


6. Ewing JR, Brown SL, Nagaraja TN, Bagher-Ebadian H, Paudyal R, Panda S, Knight RA, Ding G, Jiang Q, Lu M, Fenstermacher JD: MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging; 2008 Jun;27(6):1430-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration.
  • PURPOSE: To demonstrate in the rat 9L cerebral tumor model that repeated MRI measurements can quantitate acute changes in the blood-brain distribution of Gadomer after dexamethasone administration.
  • MATERIALS AND METHODS: A total of 16 Fischer 344 rats were studied at 7T, 15 days after cerebral implantation of a 9L tumor.
  • MRI procedures employed a T-One by Multiple Read Out Pulses (TOMROP) sequence to estimate R(1) (R(1) = 1/T(1)) at 145-second intervals before and after administration of Gadomer (Bayer), a macromolecular contrast agent (CA).
  • CONCLUSION: This noninvasive MRI technique can detect drug effects on blood-brain transfer constants of CAs within two hours of administration.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Feb;90(2):300-5 [9950501.001]
  • [Cites] Br J Cancer. 1997;75(6):829-36 [9062403.001]
  • [Cites] Magn Reson Med. 1999 Sep;42(3):467-78 [10467291.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Magn Reson Med. 2005 Feb;53(2):282-93 [15678542.001]
  • [Cites] NMR Biomed. 2005 May;18(3):173-85 [15578708.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):737-40 [16261575.001]
  • [Cites] Magn Reson Med. 2005 Dec;54(6):1351-9 [16247739.001]
  • [Cites] J Cereb Blood Flow Metab. 2006 Mar;26(3):310-20 [16079791.001]
  • [Cites] J Neurosci Methods. 2006 Oct 30;157(2):238-45 [16769125.001]
  • [Cites] Magn Reson Med. 2000 Oct;44(4):563-74 [11025512.001]
  • [Cites] Acad Radiol. 2000 Nov;7(11):934-44 [11089696.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):991-1003 [11105041.001]
  • [Cites] Magn Reson Med. 2001 Jan;45(1):71-9 [11146488.001]
  • [Cites] MAGMA. 2001 May;12(2-3):128-34 [11390268.001]
  • [Cites] Magn Reson Med. 2001 Sep;46(3):465-75 [11550237.001]
  • [Cites] Magn Reson Med. 2003 Aug;50(2):283-92 [12876704.001]
  • [Cites] Magn Reson Med. 2003 Sep;50(3):493-9 [12939756.001]
  • [Cites] Neuro Oncol. 2003 Oct;5(4):235-43 [14565159.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1151-69 [14648563.001]
  • [Cites] Acta Neurochir Suppl. 2003;86:35-7 [14753399.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):138-44 [15221819.001]
  • [Cites] Br J Cancer Suppl. 1980 Apr;4:299-303 [6932940.001]
  • [Cites] J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7 [6822610.001]
  • [Cites] Cancer Res. 1983 Jul;43(7):3368-73 [6850641.001]
  • [Cites] J Neurosurg. 1983 Jun;58(6):874-84 [6854380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):695-712 [6735758.001]
  • [Cites] Prog Exp Tumor Res. 1984;27:132-53 [6091177.001]
  • [Cites] J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90 [4055928.001]
  • [Cites] J Cereb Blood Flow Metab. 1987 Dec;7(6):687-701 [3693426.001]
  • [Cites] Magn Reson Imaging. 1990;8(4):351-6 [2392022.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4764-6 [8402656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):861-8 [7591895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):627-33 [10078649.001]
  • (PMID = 18504732.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS048349-01A1; United States / NHLBI NIH HHS / HL / R01 HL070023-04; United States / NINDS NIH HHS / NS / P01 NS023393-14A19004; United States / NINDS NIH HHS / NS / NS023393-159004; United States / NINDS NIH HHS / NS / R01 NS048349; United States / NINDS NIH HHS / NS / P01 NS023393; United States / NINDS NIH HHS / NS / P50 NS023393; United States / NINDS NIH HHS / NS / P01 NS023393-14A1S19004; United States / NINDS NIH HHS / NS / NS048349-02; United States / NINDS NIH HHS / NS / NS023393-14A19004; United States / NINDS NIH HHS / NS / R01 NS048349-02; United States / NHLBI NIH HHS / HL / HL070023-01A2; United States / NINDS NIH HHS / NS / NS023393-200002; United States / NHLBI NIH HHS / HL / R01 HL070023-03; United States / NINDS NIH HHS / NS / P50 NS023393-19A10002; United States / NHLBI NIH HHS / HL / 1 R01 HL70023-01A1; United States / NINDS NIH HHS / NS / R01 NS048349-03; United States / NINDS NIH HHS / NS / NS048349-03; United States / NHLBI NIH HHS / HL / R01 HL070023-02; United States / NHLBI NIH HHS / HL / R01 HL070023; United States / NINDS NIH HHS / NS / 1 P0-1 NS 23393; United States / NINDS NIH HHS / NS / NS023393-14A1S19004; United States / NINDS NIH HHS / NS / R01 NS048349-04; United States / NINDS NIH HHS / NS / P01 NS023393-200002; United States / NINDS NIH HHS / NS / NS048349-04; United States / NHLBI NIH HHS / HL / R01 HL070023-01A2; United States / NINDS NIH HHS / NS / NS023393-19A10002; United States / NINDS NIH HHS / NS / NS048349-01A1; United States / NHLBI NIH HHS / HL / HL070023-02; United States / NINDS NIH HHS / NS / P01 NS023393-159004; United States / NHLBI NIH HHS / HL / HL070023-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contrast Media; 0 / gadomer 17; 451W47IQ8X / Sodium Chloride; 7S5I7G3JQL / Dexamethasone; AU0V1LM3JT / Gadolinium
  • [Other-IDs] NLM/ NIHMS74050; NLM/ PMC2575657
  •  go-up   go-down


7. Banevičius G, Rugytė D, Macas A, Tamašauskas A, Stankevičius E: The effects of sevoflurane and propofol on cerebral hemodynamics during intracranial tumors surgery under monitoring the depth of anesthesia. Medicina (Kaunas); 2010;46(11):743-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of sevoflurane and propofol on cerebral hemodynamics during intracranial tumors surgery under monitoring the depth of anesthesia.
  • Hemodynamic effects during cerebral tumor resection surgery under monitoring the depth of anesthesia and during recovery in sevoflurane- or propofol-anesthetized patients have not been previously compared.
  • OBJECTIVE: To compare cerebral hemodynamic changes using transcranial Doppler sonography during sevoflurane or propofol anesthesia under state entropy (SE) monitoring, and during recovery period.
  • Cerebral blood flow velocity (Vmean) in the middle cerebral artery was evaluated at baseline, after tracheal intubation, opening of the dura mater, tumor resection, skin closure, extubation, and two hours after extubation.
  • Cerebrovascular resistance index (RAP), estimated cerebral perfusion pressure (eCPP), and cerebral blood flow index (CBFI) were calculated off-line.
  • CONCLUSIONS: At the comparable depth of anesthesia for intracranial tumors surgery and during recovery, sevoflurane had no major effect on cerebral circulation measured by transcranial Doppler sonography as compared with propofol.
  • [MeSH-major] Anesthetics, Intravenous / pharmacology. Brain / surgery. Brain Neoplasms / surgery. Cerebrovascular Circulation / drug effects. Methyl Ethers / pharmacology. Propofol / pharmacology
  • [MeSH-minor] Adolescent. Adult. Anesthesia, Intravenous. Blood Flow Velocity / drug effects. Female. Hemodynamics / drug effects. Humans. Intraoperative Period. Male. Middle Aged. Middle Cerebral Artery / drug effects. Monitoring, Intraoperative. Postoperative Period. Prospective Studies. Ultrasonography, Doppler, Transcranial. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PROPOFOL .
  • Hazardous Substances Data Bank. Sevoflurane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21467832.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Methyl Ethers; 38LVP0K73A / sevoflurane; YI7VU623SF / Propofol
  •  go-up   go-down


8. Arismendi-Morillo GJ, Fernández-Abreu M, Añez-Moreno RE: [Clinical and tomographic aspects of hemorrhagic cerebrovascular disease associated with hypertensive crisis in adults under 50 years of age]. Invest Clin; 2000 Sep;41(3):149-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Aspectos clínicos y tomográficos de la enfermedad cerebrovascular hemorrágica asociada con crisis hipertensiva en adultos menores de 50 años.
  • Forty six patients, who were not under anticoagulant therapy, were not using illegal drugs, who had not a cerebral tumor disease, and who had neither arteriovenous malformations nor past traumatic episodes, were studied.
  • A significant positive relation was found between the severity of the injury (percentage of patients with an Scale Coma Glasgow < or = 8 points) and the mortality percentage for the type of HCd (r = 0.81 for ICH; p < 0.001, r = 0.98 for SAH; p < 0.001).
  • [MeSH-major] Cerebral Hemorrhage / diagnosis. Hematoma / diagnosis. Hypertension / complications. Subarachnoid Hemorrhage / diagnosis

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11029832.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] VENEZUELA
  •  go-up   go-down


9. Toung TJ, Tyler B, Brem H, Traystman RJ, Hurn PD, Bhardwaj A: Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J Neurosurg Anesthesiol; 2002 Jul;14(3):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor.
  • Cerebral edema commonly accompanies brain tumors and frequently leads to lethal intracranial compartmental shifts and elevated intracranial pressure.
  • Therapeutic modalities for tumor-associated cerebral edema include diuretics, osmotherapy, and corticosteroids.
  • Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes.
  • The effects of continuous HS infusion in brain tumor-associated edema have not been previously reported.
  • Therefore, we tested the hypothesis that HS given as a continuous intravenous infusion ameliorates tumor-associated edema in a rat model of brain tumor.
  • 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g).
  • Hemispheric water content ipsilateral (IH) and contralateral to tumor implantation was determined at day 13 by wet-to-dry weight ratio after 48 hours of therapy.
  • Ipsilateral hemispheric water content (mean +/- SEM) was significantly increased in rats with intracranial tumor on day 11 (80.3 +/- 0.5%) (n = 7) and day 13 (81.4 +/- 0.3%) (n = 10), as compared to naive weight-matched rats without tumor implant (79.3 +/- 0.1%) (n = 13) (P <.05).
  • Continuous HS infusion attenuated cerebral edema in the affected hemisphere as well as the contralateral noninjured hemisphere to a larger extent than was observed with furosemide or mannitol.
  • These findings suggest a potential new treatment strategy for tumor-associated cerebral edema.
  • [MeSH-major] Brain Edema / drug therapy. Brain Edema / etiology. Brain Neoplasms / complications. Saline Solution, Hypertonic / therapeutic use
  • [MeSH-minor] Animals. Body Water / metabolism. Brain Chemistry / drug effects. Diuretics / therapeutic use. Diuretics, Osmotic / therapeutic use. Female. Furosemide / therapeutic use. Mannitol / therapeutic use. Neoplasm Transplantation. Osmolar Concentration. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172290.001).
  • [ISSN] 0898-4921
  • [Journal-full-title] Journal of neurosurgical anesthesiology
  • [ISO-abbreviation] J Neurosurg Anesthesiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS20020; United States / NINDS NIH HHS / NS / NS33668; United States / NCI NIH HHS / CA / U01 CA52857
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Diuretics, Osmotic; 0 / Saline Solution, Hypertonic; 3OWL53L36A / Mannitol; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


10. Hentschel S, Toyota B: Intracranial malignant glioma presenting as subarachnoid hemorrhage. Can J Neurol Sci; 2003 Feb;30(1):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Cerebral aneurysms are the predominant cause of spontaneous subarachnoid hemorrhage (SAH).
  • Cerebral neoplasms are clearly on this list but are most commonly meningiomas or metastatic lesions.
  • This article details a case of a neoplasm that presented exclusively with SAH.
  • CLINICAL PRESENTATION: A 40-year-old male presented with a SAH with normal cerebral angiography.
  • CONCLUSION: An affirmation is made that patients experiencing 'angiographically-negative' SAH should undergo MRI, occasionally on a serial basis, to exclude other etiologies for hemorrhage, including neoplasia.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Cerebral Angiography. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Seizures / drug therapy. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619787.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


11. Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A, Sugisaki Y: Tracking cell invasion of human glioma cells and suppression by anti-matrix metalloproteinase agent in rodent brain-slice model. Brain Tumor Pathol; 2002;19(2):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracking cell invasion of human glioma cells and suppression by anti-matrix metalloproteinase agent in rodent brain-slice model.
  • Tumor spheroid was implanted into the caudate nucleus-putamen of a severely compromised immunodeficient (SCID) mouse brain slice.
  • To allow quantitative assessment of tumor cell invasion, the invasion area index was measured on days 1, 3, 5, and 7 by a fluorescence stereomicroscope and an image analyzer in the presence of varying concentrations of SI-27.
  • Laser confocal microscopy indicated that the tumor cells penetrated through the brain slice.
  • This model enabled unequivocal periodic tracking of individual invading tumor cells in the normal brain.
  • The significant suppression of glioma cell invasion by SI-27 indicates that anti-matrix metalloproteinase (MMP) treatment may represent an important future therapeutic strategy for malignant cerebral neoplasms.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Enzyme Inhibitors / pharmacology. Glioma / pathology. Matrix Metalloproteinase Inhibitors. Oligopeptides / pharmacology
  • [MeSH-minor] Animals. Cell Line. Cell Transplantation. Clone Cells. Flow Cytometry. Green Fluorescent Proteins. Humans. In Vitro Techniques. Luminescent Proteins. Mice. Mice, SCID. Neoplasm Invasiveness / pathology. Neoplasm Transplantation. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Luminescent Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / Oligopeptides; 0 / SI 27; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


12. Miguel PS, Fernández G, Vasallo FJ, Hortas M, Lorenzo JR, Rodríguez I, Ortiz-Rey JA, Antón I: Neurobrucellosis mimicking cerebral tumor: case report and literature review. Clin Neurol Neurosurg; 2006 Jun;108(4):404-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurobrucellosis mimicking cerebral tumor: case report and literature review.
  • We are reporting a case of neurobrucellosis that was clinically and radiologically indistinguishable from a cerebral tumor.
  • We suggest that patients with granulomatous encephalitis, without a clear etiological agent, should be studied for Brucella.
  • [MeSH-major] Brain / microbiology. Brain Neoplasms / diagnosis. Brucellosis / microbiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644407.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 17
  •  go-up   go-down


13. Fiorillo A, Maggi G, Martone A, Migliorati R, D'Amore R, Alfieri E, Greco N, Cirillo S, Marano I: Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery. J Neurooncol; 2001 May;52(3):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the first reported case of long remission of abdominal metastases spread through a ventriculo-peritoneal shunt in an infant diagnosed, four years ago, at age 1 year and 10 months, to have cerebral medulloblastoma.
  • Two years later, while in second complete remission of his cerebral tumor, he showed abdominal metastases, successfully treated by platinum based chemotherapy and surgery.
  • This unusual favorable outcome can be explained by an extreme responsiveness of the tumor, unprotected by the blood brain barrier, to systemic chemotherapy, particularly to doxorubicin administration.
  • Searching for new tools, such as entrapment of doxorubicin in liposomes, able to overcome the blood-brain barrier and to expose brain tumors to effective drugs, probably represents the best choice for future treatment strategies of CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / pathology. Medulloblastoma / secondary. Peritoneal Neoplasms / secondary. Ventriculoperitoneal Shunt / adverse effects
  • [MeSH-minor] Carboplatin / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Hydrocephalus / surgery. Hydrocephalus / therapy. Hydroxyurea / administration & dosage. Infant. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Remission Induction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1988 Dec;4(6):321-4 [3245941.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):2-5 [9548331.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):872-7 [2033446.001]
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):171-9 [8329301.001]
  • [Cites] Pediatr Neurosurg. 1994;20(1):19-29 [8142278.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):265-71 [8869053.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):10-4 [9548333.001]
  • [Cites] Nucl Med Commun. 1997 Jan;18(1):17-23 [9061696.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):403-10 [8211658.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):1029-37 [7490617.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):149-54 [9120544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):833-41 [597384.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):388-96 [9298275.001]
  • [Cites] Am Surg. 1988 Jan;54(1):50-5 [3276260.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Childs Nerv Syst. 1998 Jun;14(6):227-9 [9694333.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):69-74 [8817417.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):151-5 [1432032.001]
  • [Cites] Childs Nerv Syst. 1994 Jan;10(1):2-12 [8194058.001]
  • [Cites] Childs Nerv Syst. 1995 Oct;11(10):574-8 [8556723.001]
  • (PMID = 11519858.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


14. Legras A, Labarthe F, Maillot F, Garrigue MA, Kouatchet A, Ogier de Baulny H: Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations. Crit Care Med; 2002 Jan;30(1):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • X-linked inherited ornithine transcarbamylase deficiency is the most frequent urea cycle disorder.
  • Women, who are mostly healthy carriers, can also develop symptomatic hyperammonemia.
  • SETTING: Intensive care unit and internal medicine unit at a university hospital.
  • For the mother, the disease was overlooked despite the onset of unusual headaches and neurologic signs that mimicked a cerebral tumor 12 yrs before.
  • CONCLUSIONS: Diagnosis of urea cycle disorder should be considered in any patient with unexplained neurologic and psychiatric disorders with selective anorexia, even in adulthood.
  • Unexplained coma with cerebral edema and respiratory alkalosis requires urgent measurement of ammonemia and metabolic work-up.

  • Hazardous Substances Data Bank. Phenylbutazone .
  • Hazardous Substances Data Bank. SODIUM BENZOATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11902270.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.3.3 / Ornithine Carbamoyltransferase; GN5P7K3T8S / Phenylbutazone; OJ245FE5EU / Sodium Benzoate
  •  go-up   go-down


15. Paradowski B, Zagrajek MM: Epilepsy in middle-aged and elderly people: a three-year observation. Epileptic Disord; 2005 Jun;7(2):91-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An analysis of the medical documentation and investigation of 130 cases of epilepsy diagnosed in a group of people over 50 years of age (average: 65.4 years) revealed that the most common type of seizure in the group studied was partial (66.2%), followed by seizures with secondary generalization (33.8%).
  • Moreover, some drugs, such as L-dopa and Baclofen, might have been related to the epileptic seizures.
  • In the study group of patients with initially unknown seizure etiology, some diseases, such as cerebral tumor or colon and pancreatic neoplasm, were diagnosed during follow-up examination.
  • [MeSH-minor] Aged. Aged, 80 and over. Brain Injuries / complications. Brain Neoplasms / complications. Electroencephalography. Epilepsy, Complex Partial / diagnosis. Epilepsy, Complex Partial / etiology. Epilepsy, Tonic-Clonic / diagnosis. Epilepsy, Tonic-Clonic / etiology. Female. Humans. Leukoaraiosis / complications. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929910.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Adukauskiene D, Bivainyte A, Radaviciūte E: [Cerebral edema and its treatment]. Medicina (Kaunas); 2007;43(2):170-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral edema and its treatment].
  • Cerebral edema is a life-threatening condition that develops as a result of an inflammatory reaction.
  • Most frequently, this is the consequence of cerebral trauma, massive cerebral infarction, hemorrhages, abscess, tumor, allergy, sepsis, hypoxia, and other toxic or metabolic factors.
  • At present, the following types of cerebral edema are differentiated: the vasogenic cerebral edema resulting from an increased permeability of the endothelium of cerebral capillaries to albumin and other plasma proteins; the cytotoxic cerebral edema resulting from the exhaustion of the energy potential of cell membranes without damage to the barrier; the hydrostatic cerebral edema resulting from disturbance of the autoregulation of cerebral blood circulation; the osmotic cerebral edema resulting from dilution of blood; and the interstitial cerebral edema resulting from acute hydrocephaly.
  • Some authors also differentiate ischemic cerebral edema.
  • At present, when various traumas and traumatic cerebral injuries are frequent causes of death in young people, treatment strategy for cerebral edema is of utmost importance.
  • It is important to ensure proper positioning of the patient--the head should be tilted at 30 degrees in order to optimize the cerebral perfusion pressure and control of the increase in intracranial pressure.
  • Slightly positive fluid balance should be maintained using crystalloid or colloid (hypertonic-hyperoncotic) solutions, at the same time maintaining cerebral perfusion pressure exceeding 70 mmHg.
  • The treatment includes administration of antihypertensive medications, nonsteroidal antiinflammatory drugs, and barbiturates.
  • Steroids decrease the permeability of capillaries and the hemato-encephalic barrier, promoting the movement of Na(+)/K(+) ions and water through the main endothelial membrane, and therefore they are used in the treatment of vasogenic cerebral edema as well as edema caused by a cerebral tumor.
  • Glutamate and N-methyl-D-aspartate receptor antagonists improve cerebral microcirculation and metabolism.
  • Trometamol corrects cerebral acidosis.
  • Extended cerebral edema is treated surgically via a bilateral decompressive craniotomy, sometimes including craniotomy of lateral and posterior fossae.
  • The treatment of cerebral edema is complex, and positive results may be expected only if the diagnosis and the provision of assistance are timely.

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329953.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Free Radicals
  • [Number-of-references] 19
  •  go-up   go-down


17. Tonon E, Scotton PG, Gallucci M, Vaglia A: Brain abscess: clinical aspects of 100 patients. Int J Infect Dis; 2006 Mar;10(2):103-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To verify if, in the last two decades, there have been any changes in epidemiological, clinical, diagnostic, therapeutic and prognostic aspects of patients with brain abscess.
  • RESULTS: Post-surgical abscesses were more frequent than those related to contiguous infections and the spectrum of etiologic agents was very heterogeneous.
  • A cerebral neoplasm was the initial neuroradiological diagnosis in 13 patients; 72 patients underwent a neurosurgical procedure.
  • CONCLUSION: With the exception of some epidemiological aspects, which varied from the literature, in spite of the improvements in diagnostic procedures and treatment, no significant changes occurred in the prognosis of patients with brain abscess.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310393.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


18. Michelucci R: Optimizing therapy of seizures in neurosurgery. Neurology; 2006 Dec 26;67(12 Suppl 4):S14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of antiepileptic drugs (AEDs) in the neurosurgical setting has a number of implications, including their possible role in the prevention of seizures after acute cerebral insults or brain tumors and the potential for toxicity and interactions when these agents are administered in association with radiotherapy or chemotherapy.
  • 1) AEDs should be prescribed on a short-term basis to prevent seizures occurring within the first week after a cerebral insult (trauma, neurosurgical procedure) but are ineffective to avoid true post-traumatic epilepsy or first seizures in patients with primary or secondary cerebral neoplasms.
  • 3) Enzyme-inducing AEDs, such as phenytoin, phenobarbital, and carbamazepine, may increase the clearance and reduce the clinical efficacy of corticosteroids and anticancer agents that are also metabolized by the cytochrome P450 system.
  • The newly developed AEDs that are devoid of hepatic metabolism, such as levetiracetam and gabapentin, are now recommended because of good results in preliminary studies and because they do not show interactions with anticancer agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Epilepsy / drug therapy. Epilepsy / etiology. Neurosurgical Procedures / adverse effects
  • [MeSH-minor] Anticonvulsants / adverse effects. Anticonvulsants / therapeutic use. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cerebellum / surgery. Craniocerebral Trauma / complications. Drug Interactions. Humans. Radiation Injuries

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190915.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


19. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • Complete resection and cerebral tumor location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG.
  • This suggests reliable diagnostic markers and new therapeutic approaches are needed.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]
  • [Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]
  • [Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


20. Matschke J, Tsokos M: Sudden unexpected death due to undiagnosed glioblastoma: report of three cases and review of the literature. Int J Legal Med; 2005 Sep;119(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although glioblastomas are among the most common primary cerebral neoplasms, sudden death due to these tumors is an uncommon event.
  • A search for cases of sudden unexpected death due to undiagnosed glioblastoma from a total of 14,482 cases from the archives of the Institute of Legal Medicine in Hamburg in the period of 1991-2003 revealed only one such case.
  • A comprehensive literature review on cases of sudden death due to primary cerebral neoplasms published so far revealed a total of 83 cases with only ten cases of glioblastoma (12%), whereas 55 of these cases were due to histological benign tumors (66%).
  • [MeSH-major] Brain Neoplasms / diagnosis. Death, Sudden / etiology. Glioblastoma / diagnosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1991 Apr;10(2):179-85 [1654403.001]
  • [Cites] Nihon Hoigaku Zasshi. 1993 Aug;47(4):336-9 [8397309.001]
  • [Cites] Int J Legal Med. 2004 Feb;118(1):32-6 [14625778.001]
  • [Cites] Am J Forensic Med Pathol. 1984 Jun;5(2):175-9 [6328972.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1024-30 [11473451.001]
  • [Cites] Int J Legal Med. 2004 Apr;118(2):98-100 [14634832.001]
  • [Cites] Schweiz Rundsch Med Prax. 1981 May 12;70(20):899-901 [6940113.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Arch Kriminol. 1999 Mar-Apr;203(3-4):108-16 [10378044.001]
  • [Cites] Am J Forensic Med Pathol. 1980 Mar;1(1):29-45 [6263083.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):44-50 [11825924.001]
  • [Cites] Cancer. 1965 Jan;18:117-27 [14260073.001]
  • (PMID = 15864615.001).
  • [ISSN] 0937-9827
  • [Journal-full-title] International journal of legal medicine
  • [ISO-abbreviation] Int. J. Legal Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 18
  •  go-up   go-down


21. Sharma RR, Pawar SJ, Dev EJ, Ebenezer S, Mahapatra AK: Hypersensitivity to glucocorticoids in patients with raised ICP : report of two cases. Neurol India; 2001 Dec;49(4):404-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Corticosteroids are widely used in patients with raised intracranial pressure associated with cerebral neoplasms, cerebral vascular malformations, cerebral ischaemia and benign intracranial hypertension.
  • In general clinical practice, anti-allergic, anti-inflammatory and immuno-suppressive properties of corticosteroids are commonly utilised in the management of allergic and immunological diseases.
  • [MeSH-major] Drug Hypersensitivity / etiology. Glucocorticoids / adverse effects. Intracranial Hypertension / drug therapy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11799418.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glucocorticoids
  • [Number-of-references] 11
  •  go-up   go-down


22. Essig M, Weber MA, von Tengg-Kobligk H, Knopp MV, Yuh WT, Giesel FL: Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging; 2006 Apr;17(2):89-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications.
  • Brain tumors are one of the most common neoplasms in young adults and are associated with a high mortality and disability rate.
  • Magnetic resonance imaging (MRI) is widely accepted to be the most sensitive imaging modality in the assessment of cerebral neoplasms.
  • Anatomical and functional, contrast agent-based MRI techniques allow for a better differential diagnosis, grading, and especially therapy decision, planing, and follow-up.
  • The underlying pathology of a disrupted blood-brain barrier and drug influences will be discussed.
  • An overview of the currently available contrast media and the influences of dosage, field strength, and application on the tumor tissue contrast will be given.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Contrast Media. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198225.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; AU0V1LM3JT / Gadolinium
  • [Number-of-references] 159
  •  go-up   go-down


23. Pradilla G, Azzam T, Wang PP, Domb AJ, Brem H: Gene therapy for malignant brain tumors. Expert Rev Neurother; 2003 Sep;3(5):685-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant primary and metastatic brain tumors have remained fatal in spite of major advances in diagnostic tools and the improvement of conventional therapies.
  • By using gene therapy, brain tumors can be treated by targeting their fundamental molecular defects, delivering gene-drugs to the malignant cells.
  • The possible targets for this type of treatment are progressively increasing but abundant clinical success has yet to be obtained, in part due to imperfect delivery systems.
  • In this review, the genetic fundamentals of various cerebral neoplasms and neurogenetic syndromes, different strategies used for gene therapy, various available DNA delivery systems, status of ongoing clinical trials, and possible prospects for the future are discussed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810968.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Ewing JR, Brown SL, Lu M, Panda S, Ding G, Knight RA, Cao Y, Jiang Q, Nagaraja TN, Churchman JL, Fenstermacher JD: Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab; 2006 Mar;26(3):310-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor.
  • Vasculature in and around the cerebral tumor exhibits a wide range of permeabilities, from normal capillaries with essentially no blood-brain barrier (BBB) leakage to a tumor vasculature that freely passes even such large molecules as albumin.
  • In measuring BBB permeability by magnetic resonance imaging (MRI), various contrast agents, sampling intervals, and contrast distribution models can be selected, each with its effect on the measurement's outcome.
  • Using Gadomer, a large paramagnetic contrast agent, and MRI measures of T(1) over a 25-min period, BBB permeability was estimated in 15 Fischer rats with day-16 9L cerebral gliomas.
  • For this contrast agent and experimental duration, Model 3 proved the best model, yielding the following central tumor means (+/-s.d.
  • Sizable inhomogeneity in v(D), K(i), and k(b) appeared within each tumor.
  • We conclude that employing nested models enables accurate assessment of transfer constants among areas where BBB permeability, contrast agent distribution volumes, and signal-to-noise vary.
  • [MeSH-major] Brain Neoplasms / diagnosis. Capillary Permeability. Disease Models, Animal. Gadolinium. Glioma / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Animals. Male. Rats. Rats, Inbred F344. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079791.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


25. Avila EK, Graber J: Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep; 2010 Jan;10(1):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seizures in the general population may occur for a variety of reasons, including vascular, infectious, autoimmune, genetic, and traumatic causes.
  • However, seizures as a result of cancer treatment, metabolic causes, or paraneoplastic diseases may occur in patients with systemic cancer, even in the absence of a cerebral lesion.
  • The etiology of seizures in brain tumor patients includes primary cerebral neoplasms and metastatic brain lesions.
  • The treatment for seizures in this population is multifaceted and involves surgery, radiation, chemotherapy, and antiepileptic drugs.
  • The treatment for brain tumor-associated seizures and epilepsy almost always is geared toward treating the tumor, but subsequent treatment of seizures often is necessary.
  • A pragmatic approach to this problem is essential to mitigate potential complications from treatment.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Seizures / etiology

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurophysiol. 2004 Sep-Oct;21(5):332-40 [15592007.001]
  • [Cites] Lancet Neurol. 2007 May;6(5):421-30 [17434097.001]
  • [Cites] Epilepsia. 1990;31 Suppl 3:S37-44 [2121472.001]
  • [Cites] Mayo Clin Proc. 1996 Jun;71(6):576-86 [8642887.001]
  • [Cites] Epilepsia. 2003 Jun;44(6):822-30 [12790896.001]
  • [Cites] J Neurol. 2009 Sep;256(9):1519-26 [19434440.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):349-54 [19169651.001]
  • [Cites] Arch Neurol. 2004 Mar;61(3):362-5 [15023812.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]
  • [Cites] Epilepsy Res. 1994 Jun;18(2):155-66 [7957038.001]
  • [Cites] Acta Neurol Scand. 2009 Sep;120(3):210-2 [19719809.001]
  • [Cites] Neurology. 1993 Aug;43(8):1599-601 [8351019.001]
  • [Cites] Curr Oncol Rep. 2008 Jan;10(1):63-71 [18366962.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):217-21 [18612799.001]
  • [Cites] Neurology. 2002 Nov 12;59(9 Suppl 5):S21-6 [12428028.001]
  • [Cites] Epilepsy Res. 2009 Jul;85(1):31-45 [19369037.001]
  • [Cites] Arch Neurol. 2001 Aug;58(8):1310 [11493178.001]
  • [Cites] Brain. 2011 Oct;134(Pt 10):2795-7 [22073412.001]
  • [Cites] Stereotact Funct Neurosurg. 1996-1997;67(3-4):169-82 [9311074.001]
  • [Cites] Can J Neurol Sci. 1996 May;23(2):128-31 [8738926.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):61-70 [17598071.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1261-3 [16636249.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Neurol Sci. 2009 Aug;30(4):353-9 [19415165.001]
  • [Cites] Clin Ther. 2008 Aug;30(8):1385-407 [18803983.001]
  • [Cites] Epilepsia. 2001 Apr;42(4):515-24 [11440347.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Epileptic Disord. 2005 Sep;7(3):253-96 [16162436.001]
  • [Cites] J Exp Clin Cancer Res. 2009 May 06;28:60 [19419544.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1853 [18946077.001]
  • [Cites] Clin Neurol Neurosurg. 2009 Feb;111(2):171-3 [18977587.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):275-84; discussion 284-6 [19205766.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] N Engl J Med. 1998 Sep 17;339(12):792-8 [9738086.001]
  • [Cites] Neurologist. 2008 Nov;14(6 Suppl 1):S44-54 [19225370.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):293-6 [17431542.001]
  • [Cites] Curr Opin Neurol. 1996 Dec;9(6):424-8 [9007399.001]
  • [Cites] Epilepsia. 1993 May-Jun;34(3):453-68 [8504780.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):167-74 [10982159.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):279-85 [16944312.001]
  • [Cites] J Neurol Sci. 1999 Jun 15;166(1):1-15 [10465493.001]
  • [Cites] Neurology. 2008 Aug 26;71(9):665-9 [18725591.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):340-5 [10668693.001]
  • [Cites] Neurology. 1996 Jul;47(1):83-9 [8710130.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E5 [16048291.001]
  • [Cites] Eur J Neurol. 2005 Sep;12(9):685-90 [16128869.001]
  • (PMID = 20425228.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 50
  •  go-up   go-down


26. Och W, Mariak Z, Smółka M, Badowski J, Koziorowski M: [Vascular endothelial growth factor expression in cerebral neoplasms]. Neurol Neurochir Pol; 2001 Nov-Dec;35(6):1071-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vascular endothelial growth factor expression in cerebral neoplasms].
  • Angiogenesis plays an important role in growth of neoplasm.
  • Among a variety of proangiogenic agents, vascular endothelial growth factor (VEGF) is regarded as a crucial mediator of tumour angiogenesis.
  • Many authors maintain that rich vasculature of the neoplasm is associated with its malignant nature.
  • [MeSH-major] Brain Neoplasms / chemistry. Brain Neoplasms / secondary. Endothelial Growth Factors / analysis. Glioma / chemistry. Lymphokines / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11987703.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


27. Bénard F, Romsa J, Hustinx R: Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med; 2003 Apr;33(2):148-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the last two decades the large volume of research involving various brain tracers has shed invaluable light on the pathophysiology of cerebral neoplasms.
  • Many, but not all studies, show a relationship between (201)Tl uptake and tumor grade.
  • Due to the overlap between tumor uptake and histologic grades, (201)Tl cannot be used as the sole noninvasive diagnostic or prognostic tool in brain tumor patients.
  • However, it may help differentiating a high-grade tumor recurrence from radiation necrosis.
  • MIBI is theoretically a better imaging agent than (201)Tl but it has not convincingly been shown to differentiate tumors according to grade.
  • Currently, MIBI's clinical role in brain tumor imaging has yet to be defined.
  • IMT, a radio-labeled amino acid analog, may be useful for identifying postoperative tumor recurrence and, in this application, appears to be a cheaper, more widely available tool than positron emission tomography (PET).
  • However, its ability to accurately identify tumor grade is limited.
  • 18 F-2-Fluoro-2-deoxy-d-glucose (FDG) PET predicts tumor grade, and the metabolic activity of brain tumors has a prognostic significance.
  • FDG-PET is effective in differentiating recurrent tumor from radiation necrosis for high-grade tumors, but has limited value in defining the extent of tumor involvement and recurrence of low-grade lesions.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Glioma / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12756647.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Methyltyrosines; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 14684-02-7 / 3-iodo-alpha-methyltyrosine; 58576-49-1 / carbon-11 methionine; 7791-12-0 / thallium chloride; 971Z4W1S09 / Technetium Tc 99m Sestamibi; AD84R52XLF / Thallium; AE28F7PNPL / Methionine; N91BDP6H0X / Choline
  • [Number-of-references] 108
  •  go-up   go-down


28. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY: The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc; 2008 Oct;44(4):222-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Malignant gliomas are the most common primary cerebral neoplasms in adults.
  • There was no mortality caused by drug toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1371-80 [10780513.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1111-39, x [17964028.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111 [17027279.001]
  • [Cites] Tumori. 2006 Jul-Aug;92(4):299-305 [17036520.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Cancer Radiother. 2005 Sep;9(5):322-31 [16095943.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):157-63 [15756519.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Can J Neurol Sci. 2007 Nov;34(4):402-10 [18062446.001]
  • (PMID = 19096681.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588321
  • [Keywords] NOTNLM ; Concomitant chemoradiotherapy / Glioblastoma / High-grade glioma / Temozolomide
  •  go-up   go-down


29. Cherif J, M'hamdi S, Osman M, Mehiri N, Zouaoui A, Zouheir S, Louzir B, Béji M: Transitory, spontaneously recovering, peripheral facial nerve palsy after vionorelbine administration. Tunis Med; 2010 Jul;88(7):513-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report the case of a 50 year old man, having stage IV lung carcinoma with a unique cerebral metastasis in the right hemisphere.
  • Focal cerebral radiotherapy was first administrated followed by intravenous chemotherapy associating vinorelbine to cisplatin.
  • The palsy has completely and spontaneously resolved at a short interval, around twenty minutes, after the end of the drug infusion.
  • Obvious cerebral tumor progression was excluded by means of CT scan; the drug was thereby administrated as scheduled until the end of the treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / drug therapy. Facial Paralysis / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582890.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


30. Balaji R, Kesavadas C, Ramachandran K, Nayak SD, Priyakumari T: Longitudinal CT and MR appearances of hemimegalencephaly in a patient with tuberous sclerosis. Childs Nerv Syst; 2008 Mar;24(3):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 3-day-old baby was referred to our institution with seizures since birth and a presumptive diagnosis of cerebral tumor detected by prenatal ultrasound.
  • Computed tomography (CT) and Magnetic Resonance (MR) imaging performed immediately after birth revealed the presence of an enhancing mass in the left cerebral hemisphere.
  • DISCUSSION: The possibility of a congenital malignant brain tumor was considered.
  • The infant was under treatment for seizures with antiepileptic drugs.
  • [MeSH-major] Brain Neoplasms / pathology. Malformations of Cortical Development / pathology. Seizures / pathology. Tuberous Sclerosis / complications


31. Robert P, Santus R, Violas X, Rémy C, Corot C: Comparison of the tumoral biodistribution of P792, a rapid clearance blood pool agent and Gd-DOTA in a C6 glioma cerebral tumor model in rats. Acad Radiol; 2002 Aug;9 Suppl 2:S521-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the tumoral biodistribution of P792, a rapid clearance blood pool agent and Gd-DOTA in a C6 glioma cerebral tumor model in rats.
  • [MeSH-major] Brain Neoplasms / pathology. Contrast Media / metabolism. Glioma / pathology. Heterocyclic Compounds / metabolism. Magnetic Resonance Imaging / methods. Organometallic Compounds / metabolism
  • [MeSH-minor] Animals. Diffusion. Female. Rats. Rats, Wistar. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12188327.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 0 / contrast agent P792; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
  •  go-up   go-down


32. Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A, Sugisaki Y: Anti-invasive effect of an anti-matrix metalloproteinase agent in a murine brain slice model using the serial monitoring of green fluorescent protein-labeled glioma cells. Neurosurgery; 2003 Jan;52(1):187-96; discussion 196-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-invasive effect of an anti-matrix metalloproteinase agent in a murine brain slice model using the serial monitoring of green fluorescent protein-labeled glioma cells.
  • OBJECTIVE: We aimed to analyze the anti-invasive effect of the anti-matrix metalloproteinase (anti-MMP) agent SI-27 by quantitative tracking of enhanced green fluorescent protein (EGFP)-labeled human malignant glioma cell lines in a brain slice model.
  • Tumor spheroid in 1 microl Matrigel was implanted into the caudate nucleus-putamen of a severe combined immunodeficient mouse brain slice.
  • To allow the quantitative assessment of tumor cell invasion, the invasion area index was measured on Days 1, 3, 5, and 7 with a fluorescence stereomicroscope and an image analyzer in the presence of various concentrations of SI-27 (0, 1, 10, 50, or 100 microg/ml).
  • Transmission electron microscopy and laser confocal microscopy indicated that the tumor cells had penetrated the brain slice and that the normal structural integrity of the brain was maintained until Day 7.
  • CONCLUSION: This model enabled unequivocal periodic tracking of individual invading tumor cells in normal brain.
  • The significant suppression of glioma cell invasion by noncytotoxic concentrations of SI-27 indicates that anti-MMP treatment may represent an important future therapeutic strategy for malignant cerebral neoplasms.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Matrix Metalloproteinase Inhibitors. Neoplasm Invasiveness / pathology. Oligopeptides / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Caudate Nucleus / pathology. Culture Techniques. Green Fluorescent Proteins. Humans. Luminescent Proteins. Male. Mice. Mice, SCID. Microscopy, Confocal. Putamen / pathology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12493117.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / Oligopeptides; 0 / SI 27; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


33. Ng KK, Ng PW, Tsang KL, Hong Kong Epilepsy Study Group: Clinical characteristics of adult epilepsy patients in the 1997 Hong Kong epilepsy registry. Chin Med J (Engl); 2001 Jan;114(1):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinical characteristics of 2952 patients with epilepsy who had received drug treatment from the neurology outpatient clinics of eight major hospitals in Hong Kong.
  • Seizure types included generalized tonic-clonic in 80.7% of patients, complex partial in 28.3%, simple partial in 14.4%, atypical absence in 2.6% and myoclonic in 1.4%, and 30.4% of patients had more than one seizure type.
  • The etiology of epilepsy was cryptogenic in 59.9%, symptomatic in 35.1% and idiopathic in 3.9%; the commonest were intracranial infection, cerebral vascular disease, cranial trauma and perinatal insult.
  • Phenytoin, carbamazepine and valproate were the most frequently used drugs and 25.9% of patients were taking more than two drugs.
  • Medical refractoriness of epilepsy was associated with a history of perinatal insult, intracranial infection, congenital brain malformation, intracranial neoplasm, cerebral vascular disease, hippocampal sclerosis, mental retardation and a history of status epilepticus (P < 0.05).

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779444.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C: Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol; 2010 Dec;12(12):1205-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, the most intractable cerebral tumor, is highly lethal.
  • Recent studies suggest that cancer stem-like cells (CSLCs) have the capacity to repopulate tumors and mediate radio- and chemoresistance, implying that future therapies may need to turn from the elimination of rapidly dividing, but differentiated, tumor cells to specifically targeting the minority of tumor cells that repopulate the tumor.
  • Interestingly, combination treatment with rapamycin and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, not only reduced the expression of NSC/progenitor markers more efficiently than single-agent treatment, but also increased the expression of βIII-tubulin, a neuronal differentiation marker.
  • [MeSH-minor] Animals. Blotting, Western. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Chromones / pharmacology. Drug Therapy, Combination. Enzyme Inhibitors / pharmacology. Humans. Immunosuppressive Agents / pharmacology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Morpholines / pharmacology. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Sirolimus / pharmacology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioblastoma.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):43-7 [15108804.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2211-20 [17132628.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):96-104 [17161482.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 [17512905.001]
  • [Cites] J Cell Sci. 2007 Aug 1;120(Pt 15):2479-87 [17646672.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63 [17911267.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] FASEB J. 2007 Dec;21(14):3777-85 [17625071.001]
  • [Cites] PLoS Med. 2008 Jan 22;5(1):e8 [18215105.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):1-17 [3275753.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Cancer Invest. 1996;14(6):551-9 [8951359.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3336-46 [15833867.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):356-68 [15967113.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):1851-63 [18606717.001]
  • [Cites] Neoplasma. 2008;55(5):369-74 [18665745.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):393-412 [18721898.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):1871-7 [19016744.001]
  • [Cites] J Neurosci Methods. 2009 Jan 30;176(2):192-9 [19215724.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):226-35 [19265662.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Cell Stem Cell. 2009 Jun 5;4(6):568-80 [19497285.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2204-10 [19671762.001]
  • [Cites] Brain Res. 2008 Nov 6;1239:216-25 [18804099.001]
  • [Cites] Cell Stem Cell. 2009 Nov 6;5(5):504-14 [19896441.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):201-7 [10930004.001]
  • [Cites] Blood. 2001 Jul 1;98(1):174-80 [11418477.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6587-97 [12242656.001]
  • [Cites] Curr Treat Options Oncol. 2002 Dec;3(6):509-24 [12392640.001]
  • [Cites] Trends Cell Biol. 2003 Feb;13(2):79-85 [12559758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):605-11 [14745879.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • (PMID = 20861085.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Immunosuppressive Agents; 0 / Morpholines; 0 / Quinolines; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; RUJ6Z9Y0DT / dactolisib; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC3018946
  •  go-up   go-down


35. Maschio M, Jandolo B: Supportive therapy in neuro-oncology. J Exp Clin Cancer Res; 2005 Mar;24(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with cerebral neoplasms often report pain or other kinds of symptoms which, even though not directly connected to the disease itself, can cause complications in the approach to therapy and worsen the quality of life of the patients.
  • Based on this hypothesis, we will discuss and examine the drugs more frequently used for supportive therapy in neuro-oncologic patients.
  • [MeSH-major] Nervous System Neoplasms / therapy
  • [MeSH-minor] Analgesia. Anticoagulants / therapeutic use. Anticonvulsants / therapeutic use. Glucocorticoids / adverse effects. Glucocorticoids / therapeutic use. Humans. Psychotropic Drugs / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943027.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Anticonvulsants; 0 / Glucocorticoids; 0 / Psychotropic Drugs
  • [Number-of-references] 54
  •  go-up   go-down






Advertisement